MRK  Merck & Company Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.79 (+1.63%)

Growth Price

Overvalued by 29.14%

Stability Price

Overvalued by 59.07%

Company Metrics

  • P/E 31.65
  • P/S 3.44
  • P/B 2.99
  • EPS 1.56
  • Cash ROIC 12.10%
  • Cash Ratio 0.84
  • Dividend 1.84 / 3.79%
  • Avg. Vol. 11.35M
  • Shares 2.79B
  • Market Cap. 137.95B

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Will 2016 Be Merck & Co. Inc.'s Best Year Yet?
Motley Fool - Feb 1, 2016
For example, adding Cubist Pharmaceuticals helped bolster Merck's therapeutic focus within acute hospital care products.
Merck & Co. Inc (MRK) Closes 1.29% Up on the Day for February 05 - Feb 5, 2016
Dow Jones component Merck & Co. Inc (MRK) saw its stock move 1.29% to $49.22, representing a per-share move of $0.628, on volume of 12.13 million shares for Friday.
Blue Chip Partners Inc. Buys 501 Shares of Merck & Co., Inc. (MRK)
Financial Market News - Feb 6, 2016
Merck & Co. logo Blue Chip Partners Inc. increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 0.9% during the fourth quarter, according to its most recent disclosure with the SEC.
BLB&B Advisors Increases Stake in Merck & Co., Inc. (MRK) - Intercooler Financial
Analytical Approach on Merck & Co. Inc. (MRK) - CWRU Observer
Merck & Co. Inc (MRK) Falls 2.86% for February 04 - Feb 4, 2016
One of the S&P 500's big losers for Thursday February 04 was Merck & Co. Inc (MRK). The company's stock fell 2.86% to $48.62 on volume of 13.82 million shares.
Merck & Co., Inc. Falters After Q4 Report
Benzinga - Feb 3, 2016
Merck & Co., Inc. (NYSE: MRK) shares are trading lower by $1.65 at $48.76 in Wednesday's session. Despite a Q4 EPS beat of $0.02 with slightly lower revenues, the Street is focusing on its lower FY 2016 outlook for EPS and revenues.
Featured Stock: Merck & Co., Inc. - CWRU Observer
Merck & Co., Inc. (NYSE:MRK) Gains Approval Of EMEND Injection From The FDA
Journal Transcript - Feb 5, 2016
A supplemental New Drug Application (sNDA) from Merck & Co., Inc. (NYSE:MRK) has won the approval of the US Food and Drug Administration (FDA).
Merck & Co., Inc: Emend Gets FDA Approval - Business Finance News
Most Active Healthcare Stocks- Merck & Co. (NYSE:MRK), AstraZeneca (NYSE:AZN ... - Seneca Globe
Will Merck and ImmunoGen Provide Breakthrough For Ovarian Cancer?
Business Finance News - Feb 4, 2016
ImmunoGen Inc. (NASDAQ:IMGN) and Merck & Co. Inc. (NYSE:MRK) have announced that they have started clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine, in combination with Merck's anti-PD-1 therapy, ...
Merck & Co. Inc (MRK) Closes 1.11% Down on the Day for February 03 - Feb 3, 2016
Dow Jones component Merck & Co. Inc (MRK) saw its stock move -1.11% to $49.85, representing a per-share move of $0.56, on volume of 15.37 million shares for Wednesday.
Earnings Reaction History: Merck & Co. Inc., 50.0% Follow-Through Indicator, 1 ...
Nasdaq - Feb 3, 2016
Merck & Co. Inc. ( MRK ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement.
Merck & Co. Inc (MRK) Closes 0.75% Down on the Day for February 02 - Feb 2, 2016
Dow Jones component Merck & Co. Inc (MRK) saw its stock move -0.75% to $50.37, representing a per-share move of $0.379, on volume of 10.13 million shares for Tuesday.